C. Gresty
AstraZeneca
22 Papers
49 Citations
C. Gresty is an academic researcher from AstraZeneca. The author has contributed to research in topics: Olaparib & Medicine. The author has an hindex of 8, co-authored 17 publications.
Chat about Author
Papers
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Maha Hussain,Joaquin Mateo,Karim Fizazi,Fred Saad,Neal D. Shore,Shahneen Sandhu,Kim N. Chi,Oliver Sartor,Neeraj Agarwal,David Olmos,Antoine Thiery-Vuillemin,Przemyslaw Twardowski,Guilhem Roubaud,Mustafa Ozguroglu,Jinyu Kang,J. Burgents,C. Gresty,Claire Corcoran,Carrie A. Adelman,Johann Sebastian de Bono +19 more
TL;DR: Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCa2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent, those who were initially assigned to receive olaparib had a significantly longer duration of overall survival than Those who were assigned to receiving enzalutamide or abiraterone plus prednisone as the control therapy.
628
Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Yvette Drew,Bella Kaufman,Susana Banerjee,A. Lortholary,Sook-Hee Hong,Young-Ae Park,Stefan Zimmermann,Patricia Roxburgh,M. Ferguson,Ricardo H. Alvarez,Susan M. Domchek,C. Gresty,Helen K. Angell,V Rocher Ros,K. Meyer,M. Lanasa,P. Herbolsheimer,M.J.A. de Jonge +17 more
TL;DR: The combination of olaparib and durvalumab was well tolerated and showed promising median PFS and DoR, and this cohort has been expanded to further explore the durability of this chemotherapy-sparing combination.
84
Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)
Susan M. Domchek,Sophie Postel-Vinay,Y.-J. Bang,Young-Ae Park,Jérôme Alexandre,J.-P. Delord,Antoine Italiano,Benoit You,S Bastian,Matthew G Krebs,Ding Wang,S. Waqar,Helen K. Angell,M. Learoyd,S. Chang,C. Gresty,P. Herbolsheimer,Bella Kaufman +17 more
TL;DR: The combination of olaparib and durvalumab was well tolerated, with no apparent overlapping toxicities and the efficacy of the combination at an early time point reached the target DCR in gBRCAm HER2-negative MBC, and warrants further investigation.
52
Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Susan M. Domchek,Sophie Postel-Vinay,S.-A. Im,Young-Ae Park,J.-P. Delord,Antoine Italiano,Jérôme Alexandre,Benoit You,S Bastian,Matthew G Krebs,Ding Wang,S. Waqar,M. Lanasa,Helen K. Angell,Zhongwu Lai,C. Gresty,L Opincar,P. Herbolsheimer,Bella Kaufman +18 more
TL;DR: The data suggest that pts with fewer prior lines of chemotherapy (0/1) had higher ORR, longer mDoR, mPFS and mOS than those with 2 prior lines.
51
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
Yung-Jue Bang,Bella Kaufman,Ravit Geva,Salomon M. Stemmer,Sook-Hee Hong,Jong Seok Lee,Susan M. Domchek,M. Lanasa,Mei Tang,C. Gresty,Helen K. Angell,L Opincar,P. Herbolsheimer,T.R. Jeffry Evans +13 more
TL;DR: The combination of olaparib and durvalumab was tolerable, with no unexpected AEs, suggesting synergistic treatment effect of the combination in some pts, and several pts with early PD showed unexpectedly long survival.
44